Episode Details

Dr. Goodyear is a Board-Certified OB/GYN and a leading expert in integrative oncology with nearly two decades of experience blending conventional and holistic cancer therapies.

He has served as medical director for multiple integrative cancer clinics, authored three books—including Breaking the Cancer Code—and is a sought-after speaker and podcaster on innovative treatments like high-dose IV vitamin C, Precision Therapy Stacking, and Low-Dose Metronomic Chemotherapy. Dr. Goodyear is dedicated to empowering both patients and physicians through education, advocacy, and cutting-edge care.

This conversation explores Dr. Nathan Goodyear’s journey from a conventional OB/GYN background into integrative oncology, shaped by both professional curiosity and personal experience. Early in his career, he began questioning the “one-size-fits-all” approach of traditional medicine after recognizing that many patients were not fully helped by standard protocols. Influenced by a compounding pharmacist and a growing interest in personalized care, he gradually incorporated integrative therapies into his practice. His path deepened after facing his own life-threatening adrenal tumor, an experience that reshaped his perspective as both a physician and a patient, ultimately leading him to fully dedicate his work to integrative cancer care.

Dr. Goodyear shares an optimistic and forward-looking vision for the future of cancer treatment, emphasizing therapies that engage and train the immune system rather than suppress it. He discusses emerging innovations such as intratumoral therapies that directly target tumors while activating immune responses, as well as the growing importance of the gut microbiome in both treatment and prevention. According to Dr. Goodyear, the microbiome plays a foundational role in immune health, with factors like diet, birth method, antibiotics, and lifestyle contributing to long-term cancer risk. He believes that future breakthroughs will come not only from advanced treatments but also from early intervention strategies that address these underlying drivers before disease develops.

The episode also highlights the importance of personalized, data-driven care. Dr. Goodyear explains how advanced testing—ranging from tumor genetics to immune signaling and inflammatory markers—can guide treatment decisions and help monitor progress. This approach allows clinicians to better understand the tumor environment, restore immune communication, and adapt therapies in real time. He emphasizes that even simple lab markers, when interpreted correctly, can provide meaningful insight into a patient’s response and prognosis.

A key theme throughout the conversation is the need to bridge the gap between conventional and integrative medicine. Dr. Goodyear advocates for collaboration rather than division, noting that patients are often left navigating conflicting information on their own. By fostering open communication, focusing on evidence, and prioritizing patient-centered care, he believes the medical community can rebuild trust and improve outcomes. He also underscores the importance of offering patients hope—grounded not in false promises, but in expanding possibilities and evolving science.

Additional topics include the role of supportive therapies such as high-dose IV vitamin C and medical cannabis. Dr. Goodyear explains how vitamin C can function differently depending on dosage—supporting the immune system at lower doses and acting as a pro-oxidative, cancer-targeting therapy at higher doses. He also discusses the use of cannabinoids, particularly CBD, as a tool for managing cancer-related pain while minimizing immune suppression associated with traditional pain medications. Throughout, he stresses the importance of ongoing research, transparency, and responsible clinical application.

Ultimately, this episode centers on a paradigm shift in cancer care—one that moves from